Artificial Intelligence in the Care of Complex Neurological Disorders

The how and the why behind Cleveland Clinic’s approach

19-NEU-5570-NI-Data-Analytics-CQD

By Andre Machado, MD, PhD, and Imad Najm, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Contemporary healthcare is awash in data. The opportunity is to make these data an asset in the service of patients rather than something that simply has to be securely stored and maintained. This requires availability of data that are not just abundant but also relevant, complete, clean and accurate — in other words, well-characterized data from real-world practice.

As part of a patient-centered institution, Cleveland Clinic’s Neurological Institute is uniquely positioned to make a difference in patients’ diagnosis and treatment through the use of artificial intelligence. We rely on a combination of extensive data availability, clinical expertise to guide collection of meaningful data in everyday practice, and analytics teams with mastery of the intricacies of healthcare data and the latest technologies. We believe a focus on harnessing the power of well-characterized, real-world data is essential to delivering on the promise of artificial intelligence in healthcare.

Also central to success is an active collaboration between our technical analytics teams and our multispecialty clinical teams, with inclusion of patient perspectives at every opportunity. Regardless of how sophisticated one’s data analytics may be, they are of little value if not applied to what clinicians identify as the factors that matter most in a given disease state and impact real-world patient care. Likewise, rich and revealing data are powerless if not integrated in a way that fits smoothly into a clinical workflow that clinicians will want to adopt.

Advertisement

Similarly, once data are collected, their analysis must go beyond the realm of statisticians and algorithms to be fully informed by clinicians’ input if they are ever to yield insights that will guide patient care in relevant, meaningful ways.

This type of collaboration is beginning to yield dividends in neurological care at Cleveland Clinic and beyond, as detailed in several recent reports from our teams on this Consult QD website:

As these reports suggest, much of the future of neurological care resides in tapping the power of well-characterized big data. But doing so involves an abundance of challenges. These are still early days, but it’s already clear that corporate data giants will not be able to solve these challenges in isolation from clinical providers, at least not in a comprehensive way. What is needed is an integrated collaboration between clinical, statistical and technical experts as reflected in the articles above.

Advertisement

Dr. Machado is Chair of Cleveland Clinic’s Neurological Institute and a neurosurgeon in the Center for Neurological Restoration. Dr. Najm is the Neurological Institute’s Vice Chair for Strategy and Development and Director of the Epilepsy Center.

Related Articles

23-NEU-3516858-brain-trauma-650×450
Neurotrauma Guidelines: Where They’ve Been, Where They’re Headed and How to Make the Most of Them

Q&A with Brain Trauma Foundation guideline architect Gregory Hawryluk, MD, PhD

20-NEU-2020111 neuroimmunology_650x450
Autoimmune Neurologic Disorders: Treatable Conditions That Should Not Be Missed

Q&A with newly arrived autoimmune neurology specialist Amy Kunchok, MD

20-NEU-1984276 multimodal-monitoring_650x450
Multimodal Monitoring in the Neuro ICU: Essentials for Clinicians (Podcast)

A neurocritical care specialist shares what’s spurring growth of this new evaluation approach

central vein sign in multiple sclerosis
New Frontiers in Diagnosing and Monitoring Multiple Sclerosis (Podcast)

Get ready for central vein sign and optical coherence tomography

20-NEU-1938374-migraine_650x450
CGRP Antagonists for Decreasing Migraine Frequency: A Primer

How these new drugs fit into practice two years out from their first approvals

20-NEU-1892171 CQD_650x450_CCC-1901608_06-03-20_0443
What’s Afoot and What’s Ahead for Physical Medicine and Rehabilitation

A conversation on the state of physiatry with the AAPM&R’s Vice President

Ad